CA2422544A1 - Vecteurs viral a replication conditionnelle et utilisation de ces vecteurs - Google Patents

Vecteurs viral a replication conditionnelle et utilisation de ces vecteurs Download PDF

Info

Publication number
CA2422544A1
CA2422544A1 CA002422544A CA2422544A CA2422544A1 CA 2422544 A1 CA2422544 A1 CA 2422544A1 CA 002422544 A CA002422544 A CA 002422544A CA 2422544 A CA2422544 A CA 2422544A CA 2422544 A1 CA2422544 A1 CA 2422544A1
Authority
CA
Canada
Prior art keywords
vector
helper
cells
hiv
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002422544A
Other languages
English (en)
Inventor
Yung-Nien Chang
Xiaobin Lu
Vladimir Slepushkin
Betty Conde
Brian Davis
Qiao Yu
Yanping Yang
Randall Merling
Wei Han
Yajin Ni
Yuexia Li
Boro Dropulic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VirxSys Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2422544A1 publication Critical patent/CA2422544A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des vecteurs améliorés à réplication conditionnelle présentant une protection accrue contre la génération vecteurs ou virus capables de réplication. L'invention concerne également de procédés de préparation, de propagation et d'encapsidation sélective, de modification et d'utilisation de tels vecteurs. L'invention concerne notamment des assistants recombinés, des cellules hôtes destinés à être utilisés avec ces vecteurs améliorés, ainsi que des compositions pharmaceutiques et des cellules hôtes comprenant ces vecteurs, l'utilisation de cellules hôtes contenant les vecteurs pour l'identification de médicaments, et des procédés consistant à utiliser ces vecteurs pour déterminer une fonction génique. Les méthodes décrites comprennent en outre le traitement préventif et curatif de maladies, en particulier d'infections virales et de l'infection par le VIH.
CA002422544A 2000-09-22 2001-09-21 Vecteurs viral a replication conditionnelle et utilisation de ces vecteurs Abandoned CA2422544A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66789300A 2000-09-22 2000-09-22
US09/667,893 2000-09-22
PCT/US2001/029976 WO2002024897A2 (fr) 2000-09-22 2001-09-21 Vecteurs ameliores a replication conditionnelle, procedes de production et utilisation de ces vecteurs

Publications (1)

Publication Number Publication Date
CA2422544A1 true CA2422544A1 (fr) 2002-03-28

Family

ID=24680093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002422544A Abandoned CA2422544A1 (fr) 2000-09-22 2001-09-21 Vecteurs viral a replication conditionnelle et utilisation de ces vecteurs

Country Status (10)

Country Link
EP (1) EP1356070A2 (fr)
JP (1) JP2004524813A (fr)
AU (1) AU9307501A (fr)
CA (1) CA2422544A1 (fr)
CZ (1) CZ2003784A3 (fr)
IL (1) IL154987A0 (fr)
NO (1) NO20031293L (fr)
NZ (1) NZ525283A (fr)
RU (1) RU2301260C2 (fr)
WO (1) WO2002024897A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006624A (es) 2001-01-25 2004-11-12 Virxsys Corp Metodos y composiciones para la identificacion de la funcion de genes.
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
WO2005023313A1 (fr) * 2003-09-09 2005-03-17 Virxsys Corporation Approches a base de vecteurs de lentivirus permettant de generer une reponse immunitaire au virus de l'immunodeficience humaine
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
BR112012013664B1 (pt) 2009-12-10 2020-11-10 Turnstone Limited Partnership rabdovírus oncolítico
DK2699270T3 (en) * 2011-04-22 2017-10-02 Univ California ADENO-ASSOCIATED VIRUS VIRUSES WITH VARIANT CAPSID AND METHODS FOR USING IT
EP2718427B1 (fr) 2011-06-08 2017-01-11 Children's Hospital of Eastern Ontario Research Institute Inc. Compositions pour le traitement du glioblastome
JP2014528729A (ja) * 2011-10-05 2014-10-30 モルメド エスピーエー ウイルスベクター精製システム
RU2488633C1 (ru) * 2011-11-16 2013-07-27 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННЫЙ ПЛАЗМИДНЫЙ ВЕКТОР ДЛЯ ГЕТЕРОЛОГИЧНОЙ ЭКСПРЕССИИ РЕКОМБИНАНТНЫХ БЕЛКОВ, ВЫСОКОЧАСТОТНОЙ ИНТЕГРАЦИИ И УСИЛЕННОЙ АМПЛИФИКАЦИИ ЭКСПРЕССИОННОЙ КАССЕТЫ В КЛЕТКАХ МЛЕКОПИТАЮЩИХ, БИЦИСТРОННАЯ мРНК, СПОСОБ ПОЛУЧЕНИЯ СТАБИЛЬНЫХ ЛИНИЙ ПРОДУЦЕНТОВ РЕКОМБИНАНТНЫХ БЕЛКОВ С ИСПОЛЬЗОВАНИЕМ УКАЗАННОГО ВЕКТОРА, СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНЫХ БЕЛКОВ
US20150307559A1 (en) * 2012-12-12 2015-10-29 Children's Hospital Of Eastern Ontario Research Intitute Inc. Compositions and methods for the treatment of brain cancers
AU2014221143B2 (en) 2013-02-21 2019-02-07 Turnstone Limited Partnership Vaccine composition
RU2548816C1 (ru) * 2013-12-16 2015-04-20 Мамонтова Марина Васильевна Способ выделения микрорнк из биологических жидкостей
SG11201809684YA (en) 2016-05-13 2018-11-29 4D Molecular Therapeutics Inc Adeno-associated virus variant capsids and methods of use thereof
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
CN114174513A (zh) * 2019-07-23 2022-03-11 牛津生物医学（英国）有限公司 慢病毒载体的优化生产
US20230374451A1 (en) * 2020-09-23 2023-11-23 Regents Of The University Of Minnesota Immortalized keratinocytes, lentivirus for keratinocyte immortalization, and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69626681T2 (de) * 1995-11-28 2004-02-12 The Johns Hopkins University School Of Medicine Konditionell-replizierende virale vektoren und ihre verwendung.
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors

Also Published As

Publication number Publication date
IL154987A0 (en) 2003-10-31
JP2004524813A (ja) 2004-08-19
AU9307501A (en) 2002-04-02
WO2002024897A2 (fr) 2002-03-28
NO20031293D0 (no) 2003-03-20
NZ525283A (en) 2008-06-30
WO2002024897A9 (fr) 2003-03-20
NO20031293L (no) 2003-05-14
WO2002024897A3 (fr) 2003-07-31
EP1356070A2 (fr) 2003-10-29
RU2301260C2 (ru) 2007-06-20
CZ2003784A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
US6498033B1 (en) Lentiviral vectors
JP4384146B2 (ja) 条件付き複製ウイルスベクターおよびその用途
CA2422544A1 (fr) Vecteurs viral a replication conditionnelle et utilisation de ces vecteurs
US20040033595A1 (en) Conditionally replicating vectors for inhibiting viral infections
US5885806A (en) Methods to prepare conditionally replicating viral vectors
AU2001293075B2 (en) Conditionally replicating viral vectors and their use
AU2001293075A1 (en) Conditionally replicating viral vectors and their use
AU2002258639A1 (en) Improved conditionally replicating vectors for inhibiting viral infections

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued